Literature DB >> 28844467

Patient selection and perioperative outcomes of bypass and endovascular intervention as first revascularization strategy for infrainguinal arterial disease.

Thomas C F Bodewes1, Jeremy D Darling2, Sarah E Deery3, Thomas F X O'Donnell3, Alexander B Pothof1, Katie E Shean2, Frans L Moll4, Marc L Schermerhorn5.   

Abstract

OBJECTIVE: The optimal initial revascularization strategy remains uncertain for patients with peripheral arterial disease. The purpose of this study was to evaluate current nationwide selection and perioperative outcomes of patients undergoing bypass or endovascular intervention for infrainguinal disease in those with no prior ipsilateral revascularization.
METHODS: Patients undergoing nonemergent first-time infrainguinal revascularization were identified in the Targeted Vascular module of the National Surgical Quality Improvement Program (NSQIP) for 2011 to 2014 and stratified by symptom status (chronic limb-threatening ischemia [CLTI] or claudication). Patients treated with endovascular intervention were compared with those who underwent bypass. Multivariable logistic regression was used to evaluate current selection of patients and to establish independent associations between first-time procedures and postoperative outcomes.
RESULTS: Of 5998 first-time infrainguinal revascularizations performed, 3193 were bypass procedures (63% for CLTI) and 2805 were endovascular interventions (64% for CLTI). Current patient characteristics associated with an endovascular-first approach as opposed to bypass-first in CLTI patients were age ≥80 years, tissue loss, nonsmoking, functional dependence, diabetes, dialysis, and tibial lesions, whereas age ≥80 years, nonwhite race, nonsmoking, diabetes, and tibial lesions were associated with an endovascular approach for claudication. In comparing first-time endovascular intervention with bypass, there was no difference in 30-day mortality in CLTI patients (univariate: 2.1% vs 2.2%; adjusted: odds ratio [OR], 0.7; 95% confidence interval [CI], 0.4-1.1) or claudication patients (0.3% vs 0.6%). Among CLTI patients, endovascular-first intervention was associated with lower rates of major adverse cardiovascular event (3.6% vs 4.7%; OR, 0.6; 95% CI, 0.4-0.9), surgical site infection (0.9% vs 7.7%; OR, 0.1; 95% CI, 0.1-0.2), bleeding (8.5% vs 17%; OR, 0.4; 95% CI, 0.3-0.5), unplanned reoperation (13% vs 17%; OR, 0.7; 95% CI, 0.5-0.8), and unplanned readmission (17% vs 18%; OR, 0.8; 95% CI, 0.7-0.9). Patients with claudication undergoing endovascular-first intervention also had lower rates of major adverse cardiovascular event (0.8% vs 1.6%; OR, 0.4; 95% CI, 0.2-0.95), surgical site infection (0.7% vs 6.6%; OR, 0.1; 95% CI, 0.04-0.2), bleeding (2.3% vs 6.0%; OR, 0.3; 95% CI, 0.2-0.5), unplanned reoperation (4.3% vs 6.6%; OR, 0.6; 95% CI, 0.4-0.9), and unplanned readmission (5.9% vs 9.0%; OR, 0.6; 95% CI, 0.4-0.8). Conversely, endovascular-first intervention was associated with a higher rate of secondary revascularizations within 30 days for CLTI (4.3% vs 3.1%; OR, 1.6; 95% CI, 1.04-2.3) but not for claudication (2.6% vs 1.9%; OR, 1.7; 95% CI, 0.9-3.4).
CONCLUSIONS: An endovascular-first approach as a revascularization strategy for infrainguinal disease was associated with substantially lower early morbidity but not mortality, at the cost of higher rates of postoperative secondary revascularizations. As a national representation of first-time revascularizations, this study highlights the early endovascular perioperative benefit, although more robust long-term data are needed to adopt either one strategy or the other in select patients with peripheral arterial disease.
Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28844467      PMCID: PMC5741492          DOI: 10.1016/j.jvs.2017.05.132

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  32 in total

1.  Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy.

Authors:  Andrew W Bradbury; Donald J Adam; Jocelyn Bell; John F Forbes; F Gerry R Fowkes; Ian Gillespie; Charles Vaughan Ruckley; Gillian M Raab
Journal:  J Vasc Surg       Date:  2010-05       Impact factor: 4.268

2.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

Review 3.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.

Authors:  Michael S Conte; Frank B Pomposelli; Daniel G Clair; Patrick J Geraghty; James F McKinsey; Joseph L Mills; Gregory L Moneta; M Hassan Murad; Richard J Powell; Amy B Reed; Andres Schanzer; Anton N Sidawy
Journal:  J Vasc Surg       Date:  2015-01-28       Impact factor: 4.268

4.  Nationwide Trends of Hospital Admission and Outcomes Among Critical Limb Ischemia Patients: From 2003-2011.

Authors:  Shikhar Agarwal; Karan Sud; Mehdi H Shishehbor
Journal:  J Am Coll Cardiol       Date:  2016-03-21       Impact factor: 24.094

5.  Comparative effectiveness of peripheral vascular intervention versus surgical bypass for critical limb ischemia in the Vascular Study Group of Greater New York.

Authors:  Andrew J Meltzer; Art Sedrakyan; Abby Isaacs; Peter H Connolly; Darren B Schneider
Journal:  J Vasc Surg       Date:  2016-05-27       Impact factor: 4.268

Review 6.  Understanding objective performance goals for critical limb ischemia trials.

Authors:  Michael S Conte
Journal:  Semin Vasc Surg       Date:  2010-09       Impact factor: 1.000

7.  Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial.

Authors:  E S van der Zaag; D A Legemate; M H Prins; J A Reekers; M J Jacobs
Journal:  Eur J Vasc Endovasc Surg       Date:  2004-08       Impact factor: 7.069

8.  2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors: 
Journal:  Circulation       Date:  2011-09-29       Impact factor: 29.690

9.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16

10.  The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease.

Authors:  Thomas T Tsai; Thomas F Rehring; R Kevin Rogers; Susan M Shetterly; Nicole M Wagner; Rajan Gupta; Omid Jazaeri; Nasim Hedayati; W Schuyler Jones; Manesh R Patel; P Michael Ho; Alan S Go; David J Magid
Journal:  Circulation       Date:  2015-09-11       Impact factor: 29.690

View more
  2 in total

1.  Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes.

Authors:  Ardwan Dakhel; Moncef Zarrouk; Jan Ekelund; Stefan Acosta; Peter Nilsson; Mervete Miftaraj; Björn Eliasson; Ann-Marie Svensson; Anders Gottsäter
Journal:  Ther Adv Endocrinol Metab       Date:  2020-10-19       Impact factor: 3.565

2.  Editor's Choice - International Variations and Sex Disparities in the Treatment of Peripheral Arterial Occlusive Disease: A Report from VASCUNET and the International Consortium of Vascular Registries.

Authors:  Christian-Alexander Behrendt; Birgitta Sigvant; Jenny Kuchenbecker; Matthew J Grima; Marc Schermerhorn; Ian A Thomson; Martin Altreuther; Carlo Setacci; Alexei Svetlikov; Elin H Laxdal; Frederico Bastos Goncalves; Eric A Secemsky; E Sebastian Debus; Kevin Cassar; Barry Beiles; Adam W Beck; Kevin Mani; Daniel Bertges
Journal:  Eur J Vasc Endovasc Surg       Date:  2020-09-29       Impact factor: 7.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.